Physician profile
Frances Ward
NPI 1659364818
$1,806.69
in general payments reported to CMS, 2019-2025
13 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2021: $118 · 2022: $245 · 2023: $368 · 2024: $495 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $243.02 | 2023 | Tepezza |
| Glaukos Corporation | $230.37 | 2019-2024 | Photrexa |
| Ocular Therapeutix, INC. | $150.00 | 2025 | Dextenza |
| Bausch & Lomb Americas INC. | $139.58 | 2024 | Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $131.53 | 2024 | |
| Lkc Technologies, INC. | $130.15 | 2025 | |
| Biotissue Holdings INC. | $125.00 | 2023 | |
| Abbvie INC. | $124.59 | 2022 | |
| Dompe US, INC. | $120.06 | 2022 | |
| Kala Pharmaceuticals, INC. | $118.39 | 2021 | |
| Asd Specialty Healthcare, LLC | $104.50 | 2019 | |
| Visioneering Technologies, INC. | $96.11 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $93.39 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.